Related Experiment Video
Updated: Jun 19, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Hypofractionation: what does it mean for prostate cancer treatment?
Yixiang Liao1, Michael Joiner, Yimei Huang
1Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA. yixiang_liao@rush.edu
International Journal of Radiation Oncology, Biology, Physics
|November 3, 2009
Summary
Hypofractionation in prostate cancer radiotherapy may improve clinical outcomes, particularly for tumors with specific radiobiologic parameters. This approach shows promise for enhanced complication-free tumor control compared to standard fractionation.
Area of Science:
- Radiation Oncology
- Medical Physics
- Oncology
Background:
- Standard radiotherapy for prostate cancer involves fractionation of 2 Gy per treatment.
- Hypofractionation, delivering higher doses per fraction, is being explored to optimize treatment efficacy and reduce toxicity.
- Radiobiologic models are crucial for predicting treatment outcomes based on dose, fractionation, and tissue parameters.
Purpose of the Study:
- To explore the clinical consequences of hypofractionation in prostate cancer radiotherapy using current radiobiologic models.
- To compare the efficacy and toxicity of four hypofractionated regimens against standard fractionation.
- To assess the impact of varying biologic parameters on treatment outcomes.
Main Methods:
- Four hypofractionated regimens were compared to standard 2 Gy x 39 fractionation for prostate cancer.
- The linear-quadratic model and generalized equivalent uniform dose (gEUD) formalism were employed.
- Tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated, alongside complication-free tumor control probability (P+).
- Sensitivity analysis was performed for alpha/beta values and surviving fraction after 2 Gy (SF2).
Main Results:
- Hypofractionation predicted decreased NTCP for rectum (2.5%) and bladder (5.8%) at 6.5 Gy/fraction compared to standard fractionation.
- Tumor control probability (TCP) decreased with increasing SF2 and alpha/beta for hypofractionated regimens.
- Hypofractionated regimens showed superior P+ for SF2 = 0.4-0.5, even with alpha/beta up to 6.5 Gy.
- For less responsive tumors (SF2 = 0.6), hypofractionation was inferior to standard fractionation at lower alpha/beta.
Conclusions:
- Radiobiologic models suggest hypofractionation can improve clinical results for prostate cancer, including tumors with high alpha/beta (up to 6.5 Gy) when SF2 < 0.5.
- These findings indicate potential for enhanced complication-free tumor control with hypofractionation.
- Individual patient anatomy may influence outcomes, necessitating further large-scale clinical validation.
